Attovia Therapeutics (ATTO) vs Bambusa Therapeutics (BBTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bambusa Therapeutics is the larger company by market cap ($815.1 million vs $690.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | BBTX |
|---|---|---|
| Share price | $15.10 | $16.00 |
| Market cap | $690.26M | $815.08M |
| 1-day change | -3.08% | +2.89% |
| EPS (TTM) | $-5.53 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $17.65 |
| 52-week low | $12.94 | $13.60 |
| Distance from 52-week high | -46.07% | -9.35% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +186.09% | — |
| Average volume | 337.27K | 359.41K |
| Shares outstanding | 45.71M | 50.94M |
| Employees | 50 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 50 employees
About Bambusa Therapeutics
BBTX stock →Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees
ATTO vs BBTX FAQ
Which is bigger, Attovia Therapeutics or Bambusa Therapeutics?
Bambusa Therapeutics (BBTX) is larger, with a market capitalization of $815.08M compared with $690.26M for Attovia Therapeutics (ATTO).
Are Attovia Therapeutics and Bambusa Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.